Do Proton Pump Inhibitors (PPIs) Cause Gastric Cancer? What the Latest Nordic Study Means for Patients

The safety of proton pump inhibitors (PPIs) has been debated for decades. Since their introduction in the 1980s, concerns have periodically surfaced suggesting that long-term PPI therapy may increase the risk of gastric cancer. Several recent meta-analyses even reported a possible two-fold increase in gastric cancer risk among PPI users.

However, newer high-quality evidence from a large Nordic multinational study provides important clarification — and reassurance.

At Centrum Pharmacy, where we work closely with physicians in our community to deliver Complete, Comprehensive, Caring, and Connected Care, understanding the strength of evidence behind medication risks is critical to guiding safe and appropriate therapy.

Why Were PPIs Linked to Gastric Cancer?

PPIs such as omeprazole, pantoprazole, and esomeprazole are among the most widely prescribed medications globally. They are highly effective for:

• Gastroesophageal reflux disease (GERD)
• Peptic ulcer disease
• Prevention of NSAID-induced ulcers
• H. pylori eradication regimens
• Barrett’s esophagus

Earlier observational studies suggested a possible association between long-term PPI use and gastric adenocarcinoma. But these studies had major methodological weaknesses, including:

• Reverse causation (patients using PPIs for early, undiagnosed cancer symptoms)
• Inclusion of short-term PPI use
• Failure to separate gastric cancer subtypes
• Inadequate adjustment for Helicobacter pylori infection
• Confounding by indication

These weaknesses can falsely create an association where none exists.

The Nordic Multinational Study: A More Rigorous Approach

Researchers from Denmark, Finland, Iceland, Norway, and Sweden conducted a large population-based case-control study using prospectively collected nationwide registry data.

Study Design Highlights:

• 17,232 cases of gastric noncardia adenocarcinoma
• 172,297 matched controls
• Long-term PPI exposure defined as >1 year
• Excluded PPI use in the 12 months before diagnosis (to prevent reverse causation bias)
• Excluded gastric cardia adenocarcinoma (to avoid reflux-related confounding)
• Adjusted for:
  • H. pylori treatment
  • Peptic ulcer disease
  • Smoking-related disease
  • Alcohol-related disease
  • Obesity and type 2 diabetes
  • Use of metformin, NSAIDs, and statins

Key Result:

After controlling for these variables:

Adjusted Odds Ratio: 1.01 (95% CI 0.96–1.07)
No statistically significant association between long-term PPI use and gastric noncardia adenocarcinoma.

When major biases were removed, the previously reported association disappeared.

Why This Study Matters

An accompanying editorial emphasized that PPIs are among the most widely used medications worldwide. Understanding their true risk profile is essential.

The editorial reinforced that:

• Many previously suggested harms of PPIs (fractures, pneumonia) remain uncertain or have been challenged.
• Reverse causation is a major bias in medication harm studies.
• Low-certainty evidence should not be used to justify inappropriate deprescribing.

In other words:

We should reduce inappropriate PPI use — but not out of fear of uncertain harms.

Deprescribing should be based on lack of indication, not exaggerated risk.

What This Means for Patients

For patients who require long-term PPI therapy, this study is reassuring.

Stopping necessary PPI therapy due to overstated cancer fears could lead to:

• Uncontrolled GERD
• Recurrent ulcers
• Gastrointestinal bleeding
• Poor quality of life

However, PPIs are sometimes continued without reassessment of indication. Appropriate use remains essential.

The Centrum Pharmacy Approach: The 4 C’s in Action

At Centrum Pharmacy, we practice:

Complete Care

We assess the original indication for every chronic medication.

Comprehensive Care

We review risk factors, drug interactions, and duration of therapy.

Caring Care

We address patient concerns about media-reported risks with evidence-based discussion.

Connected Care

We collaborate directly with physicians in our community to ensure appropriate continuation, step-down, or deprescribing when clinically indicated.

Our goal is rational prescribing — not reflex discontinuation.

Bottom Line

High-quality multinational evidence shows no meaningful association between long-term PPI use and gastric noncardia adenocarcinoma after methodological biases are addressed.

PPIs should:

• Be used when clinically indicated.
• Be reassessed periodically.
• Not be stopped solely due to low-certainty cancer fears.

If you are unsure whether your PPI is still necessary, we invite you to book a medication review at Centrum Pharmacy. Thoughtful, evidence-based medication management protects patients better than alarm-driven decisions.

Disclaimer: The medical information on this site is provided as an information resource only and is not to be used or relied on for any diagnostic or treatment purposes. This information does not substitute for professional diagnosis and treatment. Please do not initiate, modify, or discontinue any treatment, medication, or supplement solely based on this information. Always seek the advice of your healthcare provider first. Full Disclaimer.